Skip to main content
ABL Diagnostics logo

ABL Diagnostics — Investor Relations & Filings

Ticker · ABLD ISIN · FR0000063034 LEI · 9695002UO0UHM0VKRH38 PA Manufacturing
Open in API
Filings indexed 107 across all filing types
Latest filing 2026-05-08 Annual Report
Country FR France
Listing PA ABLD

About ABL Diagnostics

https://www.ablsa.com

ABL Diagnostics is a molecular diagnostics company that develops and commercializes solutions for the diagnosis and management of infectious diseases. The company's offerings include in-vitro diagnostic (IVD) medical devices, PCR-based assays such as the UltraGene product line, and integrated software for data analysis and laboratory automation. ABL Diagnostics also provides the Nadis® electronic medical record (EMR) system for clinical data management. The company specializes in genotyping and sequencing technologies, with a primary focus on monitoring drug resistance in viral infections like HIV and viral hepatitis.

Recent filings

Filing Released Lang Actions
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Annual Report FY 2025
2026-05-08 French
Rapports financiers et d'audit annuels / Rapport financier annuel
Annual Report FY 2025
2026-05-07 French
Inside Information / Operations of the issuer (acquisitions, sales...)
Report Publication Announcement Classification · 95% confidence The document is a short announcement (under 5,000 characters) regarding a major shareholder (ABL) selling a block of shares in ABL Diagnostics. It explicitly directs the reader to the AMF's BDIF database for the actual regulatory filing details. Since it serves as an announcement of a transaction and points to an external regulatory filing rather than being the primary disclosure document itself, it fits the criteria for a Report Publication Announcement (RPA) or a general regulatory announcement. Given the specific nature of the share block sale notification, RPA is the most accurate classification.
2026-03-17 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Report Publication Announcement Classification · 95% confidence The document is a short announcement (under 5,000 characters) regarding a share transaction by a major shareholder. It explicitly states that the information has been filed with the AMF (Autorité des marchés financiers) and provides a link to the official filing in the BDIF database. According to the 'Menu vs Meal' rule, this is an announcement of a filing rather than the primary regulatory filing itself, making it a Report Publication Announcement (RPA).
2026-03-17 French
Informations privilégiées / Autres communiqués
M&A Activity Classification · 95% confidence The document is a press release announcing the termination of a non-binding letter of intent regarding a potential transaction between ABL Diagnostics and ProPhase Labs. Since this relates to the status of a merger or acquisition-related discussion (even if terminated), it falls under M&A activity. It is not a report publication announcement as it provides substantive news about corporate strategy rather than just announcing the availability of a document.
2026-02-19 French
Inside Information / Other news releases
M&A Activity Classification · 95% confidence The document is a press release announcing the termination of a non-binding Letter of Intent (LOI) regarding a potential transaction between ABL Diagnostics and ProPhase Labs. Since this relates to the status of a merger or acquisition-related negotiation, it falls under M&A activity. While it is a press release, it specifically addresses the cessation of a proposed transaction, making 'TAR' (M&A Activity) the most accurate classification.
2026-02-19 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.